West Wind (audio)
Dr. Jack West: Why the Broader FDA Approval of First Pembrolizumab Monotherapy based on KEYNOTE-042 is an Invitation to Inferior Care in Advanced NSCLC
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:20:09
- More information
Informações:
Synopsis
Dr. Jack West reviews why the new FDA approval of first line pembrolizumab monotherapy for the 1-49% PD-L1 subgroup won on a technicality and now offers a clearly inferior choice compared to far better existing standards for patients with low tumor PD-L1.
